Top

Journal of Hematology & Oncology

Published in:

Open Access 01-12-2011 | Research

Retinoic acid induces HL-60 cell differentiation via the upregulation of miR-663

Authors: Pan Jian, Zhao Wen Li, Tao Yan Fang, Wang Jian, Zhou Zhuan, Liao Xin Mei, Wu Shui Yan, Ni Jian

Published in: Journal of Hematology & Oncology | Issue 1/2011

Abstract

Background

Differentiation of the acute myeloid leukemia (AML) cell line HL-60 can be induced by all trans-retinoic acid (ATRA); however, the mechanism regulating this process has not been fully characterized.

Methods

Using bioinformatics and in vitro experiments, we identified the microRNA gene expression profile of HL-60 cells during ATRA induced granulocytic differentiation.

Results

Six microRNAs were upregulated by ATRA treatment, miR-663, miR-494, miR-145, miR-22, miR-363* and miR-223; and three microRNAs were downregulated, miR-10a, miR-181 and miR-612. Additionally, miR-663 expression was regulated by ATRA. We used a lentivirus (LV) backbone incorporating the spleen focus forming virus (SFFV-F) promoter to drive miR-663 expression, as the CMV (Cytomegalovirus) promoter is ineffective in some lymphocyte cells. Transfection of LV-miR-663 induced significant HL-60 cell differentiation in vitro.

Conclusions

Our results show miR-663 may play an important role in ATRA induced HL-60 cell differentiation. Lentivirus delivery of miR-663 could potentially be used directly as an anticancer treatment in hematological malignancies

Available only for authorised users

Takahashi N: [Induction of cell differentiation and development of new anticancer drugs]. Yakugaku Zasshi. 2002, 122: 547-563. 10.1248/yakushi.122.547.CrossRefPubMed

Erkel G, Gehrt A, Anke T, Sterner O: Induction of differentiation in acute promyelocytic leukemia cells (HL-60) by the verticillin derivative Sch 52900. Z Naturforsch C. 2002, 57: 759-767.CrossRefPubMed

Kim SH, Yoo JC, Kim TS: Nargenicin enhances 1,25-dihydroxyvitamin D(3)- and all-trans retinoic acid-induced leukemia cell differentiation via PKCbetaI/MAPK pathways. Biochem Pharmacol. 2009, 77: 1694-1701. 10.1016/j.bcp.2009.03.004.CrossRefPubMed

Wang J, Fong CC, Tzang CH, Xiao P, Han R, Yang M: Gene expression analysis of human promyelocytic leukemia HL-60 cell differentiation and cytotoxicity induced by natural and synthetic retinoics. Life Sci. 2009, 84: 576-583. 10.1016/j.lfs.2009.02.001.CrossRef

Yedjou CG, Tchounwou PB: Modulation of p53, c-fos, RARE, cyclin A, and cyclin D1 expression in human leukemia (HL-60) cells exposed to arsenic trioxide. Mol Cell Biochem. 2009, 331: 207-214. 10.1007/s11010-009-0160-z.PubMedCentralCrossRefPubMed

Pan J, Hu H, Zhou Z, Sun L, Peng L, Yu L, Sun L, Liu J, Yang Z, Ran Y: Tumor-suppressive mir-663 gene induces mitotic catastrophe growth arrest in human gastric cancer cells. Oncol Rep. 24: 105-112.

Foley NH, Bray I, Watters KM, Das S, Bryan K, Bernas T, Prehn JH, Stallings RL: MicroRNAs 10a and 10b are potent inducers of neuroblastoma cell differentiation through targeting of nuclear receptor corepressor 2. Cell Death Differ. 2011,

Gu J, Zhu X, Li Y, Dong D, Yao J, Lin C, Huang K, Hu H, Fei J: miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines. Med Oncol. 28: 211-218.

Yang H, Fang Z, Wei Y, Hu Y, Calin GA, Kantarjian HM, Garcia-Manero G: Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA. Am J Hematol. 86: 237-238.

10.

Huang B, Zhao J, Lei Z, Shen S, Li D, Shen GX, Zhang GM, Feng ZH: miR-142-3p restricts cAMP production in CD4+CD25- T cells and CD4+CD25+ TREG cells by targeting AC9 mRNA. EMBO Rep. 2009, 10: 180-185. 10.1038/embor.2008.224.PubMedCentralCrossRefPubMed

11.

Sun W, Shen W, Yang S, Hu F, Li H, Zhu TH: miR-223 and miR-142 attenuate hematopoietic cell proliferation, and miR-223 positively regulates miR-142 through LMO2 isoforms and CEBP-beta. Cell Res. 20: 1158-1169.

12.

Spierings DC, McGoldrick D, Hamilton-Easton AM, Neale G, Murchison EP, Hannon GJ, Green DR, Withoff S: Ordered progression of stage specific miRNA profiles in the mouse B2 B cell lineage. Blood. 2011,

13.

Calin GA, Pekarsky Y, Croce CM: The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia. Best Pract Res Clin Haematol. 2007, 20: 425-437. 10.1016/j.beha.2007.02.003.CrossRefPubMed

14.

Ramkissoon SH, Mainwaring LA, Ogasawara Y, Keyvanfar K, McCoy JP, Sloand EM, Kajigaya S, Young NS: Hematopoietic-specific microRNA expression in human cells. Leuk Res. 2006, 30: 643-647. 10.1016/j.leukres.2005.09.001.CrossRefPubMed

15.

Fazi F, Racanicchi S, Zardo G, Starnes LM, Mancini M, Travaglini L, Diverio D, Ammatuna E, Cimino G, Lo-Coco F: Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. Cancer Cell. 2007, 12: 457-466. 10.1016/j.ccr.2007.09.020.CrossRefPubMed

16.

Merkerova M, Belickova M, Bruchova H: Differential expression of microRNAs in hematopoietic cell lineages. Eur J Haematol. 2008, 81: 304-310. 10.1111/j.1600-0609.2008.01111.x.CrossRefPubMed

17.

Stamatopoulos B, Meuleman N, Haibe-Kains B, Saussoy P, Van Den Neste E, Michaux L, Heimann P, Martiat P, Bron D, Lagneaux L: microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood. 2009, 113: 5237-5245. 10.1182/blood-2008-11-189407.CrossRefPubMed

18.

Eyholzer M, Schmid S, Schardt JA, Haefliger S, Mueller BU, Pabst T: Complexity of miR-223 regulation by CEBPA in human AML. Leuk Res. 34: 672-676.

19.

Naguibneva I, Ameyar-Zazoua M, Polesskaya A, Ait-Si-Ali S, Groisman R, Souidi M, Cuvellier S, Harel-Bellan A: The microRNA miR-181 targets the homeobox protein Hox-A11 during mammalian myoblast differentiation. Nat Cell Biol. 2006, 8: 278-284. 10.1038/ncb1373.CrossRefPubMed

20.

Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, Volinia S, Alder H, Liu CG, Rassenti L: Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 2006, 66: 11590-11593. 10.1158/0008-5472.CAN-06-3613.CrossRefPubMed

21.

Dou LP, Li YH, Xu CW, Wang LL, Yu L: [Targeted regulation of mll-af4 fusion gene by miR-142-3p]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 18: 1595-1599.

22.

Takeda M, Ogino S, Umemoto R, Sakakura M, Kajiwara M, Sugahara KN, Hayasaka H, Miyasaka M, Terasawa H, Shimada I: Ligand-induced structural changes of the CD44 hyaluronan-binding domain revealed by NMR. J Biol Chem. 2006, 281: 40089-40095. 10.1074/jbc.M608425200.CrossRefPubMed

23.

Sham RL, Phatak PD, Belanger KA, Packman CH: The effect of dexamethasone on functional properties of HL60 cells during all-trans retinoic acid induced differentiation. Are there implications for the retinoic acid syndrome?. Blood Cells Mol Dis. 1996, 22: 139-149. 10.1006/bcmd.1996.0021.CrossRefPubMed

24.

Verlinden L, Verstuyf A, Mathieu C, Tan BK, Bouillon R: Differentiation induction of HL60 cells by 1,25(OH)2D3, all trans retinoic acid, rTGF-beta2 and their combinations. J Steroid Biochem Mol Biol. 1997, 60: 87-97. 10.1016/S0960-0760(96)00174-4.CrossRefPubMed

25.

Reichman TW, Albanell J, Wang X, Moore MA, Studzinski GP: Downregulation of telomerase activity in HL60 cells by differentiating agents is accompanied by increased expression of telomerase-associated protein. J Cell Biochem. 1997, 67: 13-23. 10.1002/(SICI)1097-4644(19971001)67:1<13::AID-JCB2>3.0.CO;2-Z.CrossRefPubMed

26.

Barber N, Belov L, Christopherson RI: All-trans retinoic acid induces different immunophenotypic changes on human HL60 and NB4 myeloid leukaemias. Leuk Res. 2008, 32: 315-322. 10.1016/j.leukres.2007.04.013.CrossRefPubMed

27.

Ketteler R, Glaser S, Sandra O, Martens UM, Klingmuller U: Enhanced transgene expression in primitive hematopoietic progenitor cells and embryonic stem cells efficiently transduced by optimized retroviral hybrid vectors. Gene Ther. 2002, 9: 477-487. 10.1038/sj.gt.3301653.CrossRefPubMed

28.

Tili E, Michaille JJ, Adair B, Alder H, Limagne E, Taccioli C, Ferracin M, Delmas D, Latruffe N, Croce CM: Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD. Carcinogenesis. 31: 1561-1566.

29.

Dreher A, Rossing M, Kaczkowski B, Nielsen FC, Norrild B: Differential expression of cellular microRNAs in HPV-11 transfected cells. An analysis by three different array platforms and qRT-PCR. Biochem Biophys Res Commun. 403: 357-362.

30.

Pizzimenti S, Ferracin M, Sabbioni S, Toaldo C, Pettazzoni P, Dianzani MU, Negrini M, Barrera G: MicroRNA expression changes during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal, a product of lipid peroxidation. Free Radic Biol Med. 2009, 46: 282-288. 10.1016/j.freeradbiomed.2008.10.035.CrossRefPubMed

31.

Kasashima K, Nakamura Y, Kozu T: Altered expression profiles of microRNAs during TPA-induced differentiation of HL-60 cells. Biochem Biophys Res Commun. 2004, 322: 403-410. 10.1016/j.bbrc.2004.07.130.CrossRefPubMed

32.

Lutherborrow M, Bryant A, Jayaswal V, Agapiou D, Palma C, Yang YH, Ma DD: Expression profiling of cytogenetically normal acute myeloid leukemia identifies microRNAs that target genes involved in monocytic differentiation. Am J Hematol. 86: 2-11.

33.

Ni CW, Qiu H, Jo H: MicroRNA-663 upregulated by oscillatory shear stress plays a role in inflammatory response of endothelial cells. Am J Physiol Heart Circ Physiol.

Title: Retinoic acid induces HL-60 cell differentiation via the upregulation of miR-663
Authors: Pan Jian
Zhao Wen Li
Tao Yan Fang
Wang Jian
Zhou Zhuan
Liao Xin Mei
Wu Shui Yan
Ni Jian
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: Journal of Hematology & Oncology / Issue 1/2011
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/1756-8722-4-20

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2011

Relevance of JAK2V617F positivity to hematological diseases - survey of samples from a clinical genetics laboratory

High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma

Allogeneic hematopoietic stem cell transplantation for acute leukemia with Gilbert's syndrome

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance

Enhanced self-renewal of hematopoietic stem/progenitor cells mediated by the stem cell gene Sall4

Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP

Keynote webinar | Spotlight on antibody–drug conjugates in cancer